MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414647 | Name: Otamixaban HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Otamixaban HCl is an experimental injectable anticoagulant direct factor Xa inhibitor, that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.

Chemical Structure

Otamixaban HCl
Otamixaban HCl
CAS#409081-12-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 414647

Name: Otamixaban HCl

CAS#: 409081-12-5 (HCl)

Chemical Formula: C25H27ClN4O4

Exact Mass: 482.1721

Molecular Weight: 482.97

Elemental Analysis: C, 62.17; H, 5.64; Cl, 7.34; N, 11.60; O, 13.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
409081-12-5 (HCl); 193153-04-7 (free base)
Synonym
Otamixaban hydrochloride; Otamixaban HCl; RPR130673 HCl; RPR 130673 HCl; RPR-130673 HCl
IUPAC/Chemical Name
Methyl (2R,3R)-2-(3-amidinobenzyl)-3-((4-(1-oxido-4-pyridinyl)benzoyl)amino)butanoate hydrochloride
InChi Key
ROKCPUOLRIBSQQ-BYYQELCVSA-N
InChi Code
InChI=1S/C25H26N4O4.ClH/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19;/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30);1H/t16-,22-;/m1./s1
SMILES Code
C[C@@H](NC(C1=CC=C(C2=CC=[N+]([O-])C=C2)C=C1)=O)[C@@H](CC3=CC=CC(C(N)=N)=C3)C(OC)=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 482.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Roberts A. Anticoagulation therapy: Otamixaban fails in NSTE-ACS. Nat Rev Cardiol. 2013 Nov;10(11):615. doi: 10.1038/nrcardio.2013.134. Epub 2013 Sep 17. PubMed PMID: 24042230. 2: Steg PG, Mehta SR, Pollack CV Jr, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim JH, Jeong MH, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS; TAO Investigators. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA. 2013 Sep 18;310(11):1145-55. doi: 10.1001/jama.2013.277165. PubMed PMID: 23995608. 3: Steg PG, Mehta SR, Pollack CV Jr, Bode C, Gaudin C, Fanouillere K, Moryusef A, Wiviott SD, Sabatine MS. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J. 2012 Dec;164(6):817-24.e13. doi: 10.1016/j.ahj.2012.10.001. Epub 2012 Nov 7. PubMed PMID: 23194481. 4: Doggrell SA. New drugs for the treatment of coronary artery syndromes: otamixaban and ticagrelor. Expert Opin Pharmacother. 2010 Feb;11(2):325-9. doi: 10.1517/14656560903473173. PubMed PMID: 20088750. 5: Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. Lancet. 2009 Sep 5;374(9692):762-4. doi: 10.1016/S0140-6736(09)61529-4. Epub 2009 Aug 28. PubMed PMID: 19717186. 6: Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009 Sep 5;374(9692):787-95. doi: 10.1016/S0140-6736(09)61454-9. Epub 2009 Aug 28. Erratum in: Lancet. 2009 Oct 31;374(9700):1502. PubMed PMID: 19717184. 7: Guertin KR, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem. 2007;14(23):2471-81. Review. PubMed PMID: 17979700. 8: Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J; SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation. 2007 May 22;115(20):2642-51. Epub 2007 May 14. PubMed PMID: 17502577. 9: Hinder M, Frick A, Jordaan P, Hesse G, Gebauer A, Maas J, Paccaly A. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther. 2006 Dec;80(6):691-702. PubMed PMID: 17178269. 10: Nutescu EA, Pater K. Drug evaluation: the directly activated Factor Xa inhibitor otamixaban. IDrugs. 2006 Dec;9(12):854-65. Review. PubMed PMID: 17139573. 11: Sakai T, Kawamoto Y, Tomioka K. Asymmetric synthesis of intermediates for otamixaban and premafloxacin by the chiral ligand-controlled asymmetric conjugate addition of a lithium amide. J Org Chem. 2006 Jun 9;71(12):4706-9. PubMed PMID: 16749814. 12: Hinder M, Frick A, Rosenburg R, Hesse G, Ozoux ML, Laux V, Scholtz H, Gebauer A, Paccaly A. Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. Thromb Haemost. 2006 Feb;95(2):224-8. PubMed PMID: 16493482. 13: Paccaly A, Ozoux ML, Chu V, Simcox K, Marks V, Freyburger G, Sibille M, Shukla U. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost. 2005 Dec;94(6):1156-63. PubMed PMID: 16411387. 14: Paccaly A, Frick A, Ozoux ML, Chu V, Rosenburg R, Hinder M, Shukla U, Jensen BK. Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006 Jan;46(1):45-51. PubMed PMID: 16397283. 15: Paccaly A, Frick A, Rohatagi S, Liu J, Shukla U, Rosenburg R, Hinder M, Jensen BK. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol. 2006 Jan;46(1):37-44. PubMed PMID: 16397282. 16: Hinder M, Paccaly A, Frick A, Shukla U, Simcox K, Miller B, Gebauer A. Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers. Thromb Haemost. 2005 Apr;93(4):794-5. PubMed PMID: 15841331.

View History

DCFBC

DCFBC

GSK2018682 HCl

GSK2018682 HCl

AZ1508

AZ1508

Padeliporfin potassium

Padeliporfin potassium

PUL-042 component PAM2

PUL-042 component PAM2

Pudafensine

Pudafensine